Medicibio Co.,ltd

MediciBIO Co, LTD is a biotechnology company, actively pursuing research in developing lipid-based nanoparticle (NP) platform technology and innovative new drugs for genetic diseases. Since its foundation in 2021, like the meaning of “the Medici Effect”, MediciBIO has derived innovative ideas through integrating DDS with nano-biotechnology, to create an innovative fusion technology in gene delivery area. We research and develop “Medici Ionizable Lipid” and “Medici Targeting Lipid” as our unique gene carriers for next generation lipid nanoparticle (LNP). The LNP composed of Medici Ionizable Lipid, Medici-20 exhibits the superior gene delivery efficacy after IV injection in comparison to the LNPs composed of a FDA-approved ionizable lipid (MC-3 or SM-102), and notably have the significant lower and minimal immunogenicity and inflammation profiles as a carrier. Therefore, Medici-20 is eligible for the development of RNA or DNA therapeutics that necessitate multiple as well as frequently repeated administration even with inter-injection interval less than a week. Another LNP composed of Medici ionizable lipid, Medici-305, demonstrates favorable localized gene delivery efficacy in muscle with a marked reduction in undesired systemic exposure after IM injection. The local delivery and reduced systemic exposure offered by an Medici-305-based LNP may potentially result in fewer excessive systemic reactogenicity, such as headache, systemic inflammation, fever, or fatigue. Therefore, Medici-305 can be used for infectious disease vaccines as well as cancer vaccines, while most of ionizable lipids are used only for infectious disease vaccines. MediciBIO currently owns the patent rights for this structurally unique lipid; therefore, “Medici Lipid” can be used for independent product development with patent protections.